L3VLUP
ProSign in

RVMD · AMGN in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

RVMDAMGN
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • RVMD
  • AMGN
0102030202120222023202420252026
Holders and value by quarter
QuarterRVMDAMGN
Q3 20203 holders, $388m16 holders, $16.3bn
Q4 20204 holders, $451m19 holders, $14.0bn
Q1 20215 holders, $846m16 holders, $14.5bn
Q2 20215 holders, $325m23 holders, $13.8bn
Q3 20213 holders, $133m24 holders, $11.6bn
Q4 20213 holders, $174m21 holders, $10.4bn
Q1 20223 holders, $174m23 holders, $9.9bn
Q2 20223 holders, $189m28 holders, $9.7bn
Q3 20223 holders, $206m21 holders, $7.9bn
Q4 20223 holders, $263m24 holders, $9.3bn
Q1 20235 holders, $526m22 holders, $8.4bn
Q2 20237 holders, $685m26 holders, $7.4bn
Q3 20238 holders, $766m26 holders, $8.7bn
Q4 20238 holders, $1.0bn24 holders, $8.4bn
Q1 202410 holders, $1.3bn25 holders, $6.7bn
Q2 20249 holders, $1.6bn20 holders, $8.0bn
Q3 202410 holders, $1.9bn21 holders, $8.8bn
Q4 202411 holders, $2.2bn20 holders, $8.2bn
Q1 20257 holders, $1.7bn25 holders, $12.0bn
Q2 20258 holders, $1.7bn20 holders, $10.2bn
Q3 20257 holders, $2.2bn17 holders, $10.4bn
Q4 202518 holders, $4.3bn19 holders, $18.0bn
Q1 202615 holders, $4.8bn15 holders, $21.4bn
Q2 202617 holders, $10.3bn23 holders, $24.9bn
RVMD

Revolution Medicines Inc

Holders
17
Reported value
$10.3bn
Buyers
16
Sellers
23

Breadth -7 among 91 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
AMGN

Amgen Inc

Holders
23
Reported value
$24.9bn
Buyers
19
Sellers
13

Breadth +6 among 91 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q2 2026

Among the 31 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only RVMD (8)

AQR Capital Management LLC, Baillie Gifford & Co, ExodusPoint Capital Management LP, Farallon Capital Management LLC, Freestone Grove Partners LP, Holocene Advisors LP, MFS Investment Management, Moore Capital Management LP

Only AMGN (14)

AllianceBernstein LP, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Hudson Bay Capital Management LP, Invesco Ltd, Neuberger Berman Group LLC, PDT Partners LLC, Squarepoint Ops LLC, Walleye Capital LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →